<\/p>\n
Ezedoc<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 ezetimibe<\/strong> (10 mg), \u03bc\u03b9\u03b1 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03b1\u03c0\u03bf\u03c1\u03c1\u03cc\u03c6\u03b7\u03c3\u03b7\u03c2 \u03c7\u03bf\u03bb\u03b7\u03c3\u03c4\u03b5\u03c1\u03cc\u03bb\u03b7\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03b1\u03bd\u03b1\u03c3\u03c4\u03ad\u03bb\u03bb\u03b5\u03b9 \u03c4\u03bf\u03bd \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ad\u03b1 NPC1L1 \u03c3\u03c4\u03bf \u03bb\u03b5\u03c0\u03c4\u03cc \u03ad\u03bd\u03c4\u03b5\u03c1\u03bf. \u0395\u03af\u03bd\u03b1\u03b9 \u03b7 go-to add-on therapy when a statin alone doesn\u2019t get LDL to target<\/strong>. On its own, ezetimibe lowers LDL-C by about 17\u201322%. Added to a statin, it produces an additional ~20\u201325% LDL reduction, totaling a 55\u201360% fall \u2014 equivalent to doubling the statin dose without the dose-related muscle or liver side effects. The \u03b4\u03b9\u03b5\u03c1\u03b5\u03cd\u03bd\u03b7\u03c3\u03b7 IMPROVE-IT<\/strong> trial (18,144 patients post-ACS) proved that adding ezetimibe to simvastatin further reduces cardiovascular events. Dose: 10\u00a0mg once daily, any time, with or without food. Generally very well-tolerated \u2014 mild GI upset, occasional myalgia, rare transaminase elevation. Avoid in severe hepatic impairment.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03b5\u03c1\u03b3\u03bf\u03c3\u03c4\u03ac\u03c3\u03b9\u03b1 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03b9\u03b5\u03c5\u03b8\u03cd\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03c3\u03c4\u03bf\u03b9\u03c7\u03b5\u03af\u03c9\u03bd \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03ac\u03bb\u03b9\u03c3\u03b7\u03c2.<\/p>\n \u03a4\u03bf Ezedoc \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03c9\u03bd \u03bb\u03b9\u03c0\u03b9\u03b4\u03af\u03c9\u03bd \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 ezetimibe<\/strong> (10 mg), \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03b5\u03c1\u03b3\u03bf\u03c3\u03c4\u03ac\u03c3\u03b9\u03bf \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd WHO-GMP. \u03a0\u03c1\u03bf\u03c3\u03c6\u03ad\u03c1\u03b5\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b5\u03c2 \u03c4\u03c9\u03bd 30, 60, 90 \u03ae 180 \u03b4\u03b9\u03c3\u03ba\u03af\u03c9\u03bd. \u0397 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03b2\u03b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03c0\u03c1\u03ce\u03c4\u03bf \u03ba\u03b1\u03b9 \u03bc\u03bf\u03bd\u03b1\u03b4\u03b9\u03ba\u03cc \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \u03c4\u03b7\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03b1\u03c0\u03bf\u03c1\u03c1\u03cc\u03c6\u03b7\u03c3\u03b7\u03c2 \u03c7\u03bf\u03bb\u03b7\u03c3\u03c4\u03b5\u03c1\u03cc\u03bb\u03b7\u03c2<\/strong> \u03ba\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b1\u03c2. \u0391\u03c1\u03c7\u03b9\u03ba\u03ae \u03b5\u03bc\u03c0\u03bf\u03c1\u03b9\u03ba\u03ae \u03bf\u03bd\u03bf\u03bc\u03b1\u03c3\u03af\u03b1: Zetia \/ Ezetrol<\/strong> (Merck, 2002).<\/p>\n Ezetimibe is a mainstay of second-line lipid management \u2014 the first choice when you need more LDL reduction than a tolerated statin dose provides, or when a patient cannot tolerate higher statin doses. It is also the most common partner in fixed-dose combinations (simvastatin\/ezetimibe = Inegy\/Vytorin; rosuvastatin\/ezetimibe = various).<\/p>\n Ezetimibe is weak as a monotherapy (~17% LDL reduction) compared to a statin (~30\u201360%); it is most powerful as an add-on.<\/p>\n \u0397 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03b2\u03b7 \u03b1\u03bd\u03b1\u03c3\u03c4\u03ad\u03bb\u03bb\u03b5\u03b9 \u03b5\u03c0\u03b9\u03bb\u03b5\u03ba\u03c4\u03b9\u03ba\u03ac \u03c4\u03bf\u03bd \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ad\u03b1 Niemann-Pick C1-Like 1 (NPC1L1)<\/strong> \u03c3\u03c4\u03bf\u03c5\u03c2 \u03b5\u03bd\u03c4\u03b5\u03c1\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1 \u03c4\u03bf\u03c5 \u03b5\u03b3\u03b3\u03cd\u03c2 \u03bb\u03b5\u03c0\u03c4\u03bf\u03cd \u03b5\u03bd\u03c4\u03ad\u03c1\u03bf\u03c5. \u039f NPC1L1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c1\u03c1\u03cc\u03c6\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c7\u03bf\u03bb\u03b7\u03c3\u03c4\u03b5\u03c1\u03cc\u03bb\u03b7\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7 \u03b4\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae \u03ba\u03b1\u03b9 \u03c4\u03b7 \u03c7\u03bf\u03bb\u03ae \u03b1\u03c0\u03cc \u03c4\u03bf \u03ad\u03bd\u03c4\u03b5\u03c1\u03bf \u03c3\u03c4\u03bf \u03b5\u03bd\u03c4\u03b5\u03c1\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03bf.<\/p>\n \u039c\u03b5 \u03c4\u03bf\u03bd NPC1L1 \u03b1\u03bd\u03b1\u03c3\u03c4\u03b1\u03bb\u03bb\u03cc\u03bc\u03b5\u03bd\u03bf:<\/p>\n \u0395\u03c0\u03b5\u03b9\u03b4\u03ae \u03b7 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03bf\u03b9 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b5\u03c2 \u03b4\u03c1\u03bf\u03c5\u03bd \u03c3\u03b5 \u03c3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ad\u03c2 \u03bf\u03b4\u03bf\u03cd\u03c2<\/strong> (absorption vs synthesis), their effects are additive. Statins reduce LDL synthesis; ezetimibe reduces LDL absorption\/input. Together they drop LDL more than either can alone, without adding to each other\u2019s side-effect profile.<\/p>\n \u0394\u03b5\u03b4\u03bf\u03bc\u03ad\u03bd\u03b1 \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03ac\u03c4\u03c9\u03bd: \u03b7 \u03b4\u03b9\u03ba\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae IMPROVE-IT<\/strong> (2015) \u03ad\u03b4\u03b5\u03b9\u03be\u03b5 \u03cc\u03c4\u03b9 \u03b7 \u03c0\u03c1\u03bf\u03c3\u03b8\u03ae\u03ba\u03b7 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03bd\u03b7\u03c2 \u03c3\u03c4\u03b7 \u03c3\u03b9\u03bc\u03b2\u03b1\u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b7 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5\u03c4\u03ac \u03b1\u03c0\u03cc ACS \u03bc\u03b5\u03af\u03c9\u03c3\u03b5 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b8\u03b5\u03c4\u03bf \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03cc \u03c4\u03b5\u03bb\u03b9\u03ba\u03cc \u03c3\u03b7\u03bc\u03b5\u03af\u03bf \u03ba\u03b1\u03c4\u03ac 6,4% (NNT 50 \u03b5\u03c0\u03af 7 \u03ad\u03c4\u03b7), \u03b5\u03c0\u03b9\u03b2\u03b5\u03b2\u03b1\u03b9\u03ce\u03bd\u03bf\u03bd\u03c4\u03b1\u03c2 \u03cc\u03c4\u03b9 \u03b7 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03bf\u03c5 LDL \u03bc\u03b5\u03c4\u03b1\u03c6\u03c1\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03c0\u03c1\u03b1\u03b3\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03b3\u03b5\u03b3\u03bf\u03bd\u03cc\u03c4\u03c9\u03bd.<\/p>\n \u03a4\u03c5\u03c0\u03b9\u03ba\u03ae \u03b4\u03cc\u03c3\u03b7:<\/strong> 10\u00a0mg once daily at any time of day, with or without food.<\/p>\n \u0397 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03b2\u03b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b1 \u03b1\u03bd\u03b5\u03ba\u03c4\u03b9\u03ba\u03ac \u03c5\u03c0\u03bf\u03bb\u03b9\u03c0\u03b9\u03b4\u03b1\u03b9\u03bc\u03b9\u03ba\u03ac \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1. \u039f\u03b9 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2 \u03b5\u03af\u03bd\u03b1\u03b9 \u03ba\u03bf\u03bd\u03c4\u03ac \u03c3\u03b5 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u03b5\u03b9\u03ba\u03bf\u03bd\u03b9\u03ba\u03bf\u03cd \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03b5 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ad\u03c2.<\/p>\n \u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 (< 5%):<\/strong><\/p>\n \u0391\u03c3\u03c5\u03bd\u03ae\u03b8\u03b9\u03c3\u03c4\u03b5\u03c2:<\/strong><\/p>\n Store Ezedoc below 25\u00b0C in a dry place, in the original blister. Keep out of reach of children.<\/p>\n Usually no. As monotherapy, ezetimibe lowers LDL by only ~17% \u2014 much less than a statin (30\u201360%). It is appropriate as monotherapy only for patients who cannot tolerate any statin at any dose. For most people, the best lipid-lowering strategy is statin first, ezetimibe added if LDL is still above target.<\/p>\n Doubling a statin dose typically adds ~6% LDL reduction (the statin \u201crule of 6\u201d). Adding ezetimibe adds ~20\u201325% LDL reduction. Adding ezetimibe is 3\u20134\u00d7 more effective<\/strong> \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03bf\u03c5, \u03ba\u03b1\u03b9 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c4\u03b7\u03bd \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03c9\u03bd \u03bc\u03c5\u03ca\u03ba\u03ce\u03bd \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u03c0\u03bf\u03c5 \u03c3\u03c7\u03b5\u03c4\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7. \u0391\u03c5\u03c4\u03cc\u03c2 \u03b5\u03af\u03bd\u03b1\u03b9 \u03bf \u03bb\u03cc\u03b3\u03bf\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03bd \u03bf\u03c0\u03bf\u03af\u03bf \u03bf\u03b9 \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b5\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 \u03b5\u03c5\u03bd\u03bf\u03bf\u03cd\u03bd \u03c4\u03bf\u03bd \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03bf\u03c5 + \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03bc\u03c0\u03b7\u03c2 \u03ad\u03bd\u03b1\u03bd\u03c4\u03b9 \u03c4\u03b7\u03c2 \u03b1\u03cd\u03be\u03b7\u03c3\u03b7\u03c2 \u03c4\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c4\u03bf\u03c5 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03bf \u03bc\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf.<\/p>\n Yes \u2014 the IMPROVE-IT trial (18,144 post-ACS patients) showed adding ezetimibe to simvastatin reduced the composite endpoint of CV death, MI, unstable angina, revascularisation, or stroke by 6.4% over 7 years. This is the landmark evidence that LDL reduction beyond statins alone still translates into real cardiovascular benefit.<\/p>\n Any time of day is fine. Unlike simvastatin (evening preferred), ezetimibe timing is not dose-dependent \u2014 pick a time you will remember consistently. Many patients take it at the same time as their statin.<\/p>\n \u03a3\u03c0\u03ac\u03bd\u03b9\u03b1. \u0397 \u03bc\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b5\u03b6\u03b5\u03c4\u03b9\u03bc\u03af\u03bc\u03c0\u03b7 \u03b4\u03b5\u03af\u03c7\u03bd\u03b5\u03b9 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2 \u03c3\u03b5 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03bf \u03b5\u03b9\u03ba\u03bf\u03bd\u03b9\u03ba\u03bf\u03cd \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5. \u038c\u03c4\u03b1\u03bd \u03c3\u03c5\u03bd\u03b4\u03c5\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b9\u03bf, \u03b4\u03b5\u03bd \u03b1\u03c5\u03be\u03ac\u03bd\u03b5\u03b9 \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac \u03c4\u03b1 \u03bc\u03c5\u03ca\u03ba\u03ac \u03c3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1 \u03c0\u03bf\u03c5 \u03c3\u03c7\u03b5\u03c4\u03af\u03b6\u03bf\u03bd\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c4\u03b1 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b9\u03b1 \u03c3\u03b5 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03bf \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b9\u03bf \u03bc\u03cc\u03bd\u03bf.<\/p>\n \u039c\u03c0\u03bf\u03c1\u03b5\u03af\u03c4\u03b5 \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 Ezedoc (10 mg) \u03b1\u03c0\u03cc \u03c4\u03bf MedsBase \u03c3\u03b5 \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b5\u03c2 \u03c4\u03c9\u03bd 30, 60, 90 \u03ae 180 \u03b4\u03b9\u03c3\u03ba\u03af\u03c9\u03bd. \u03a0\u03c1\u03b1\u03b3\u03bc\u03b1\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bc\u03b5 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ad\u03c2 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03bc\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03b3\u03bd\u03ae\u03c3\u03b9\u03b1 \u03b1\u03c0\u03bf\u03b8\u03ad\u03bc\u03b1\u03c4\u03b1 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03bc\u03b5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 WHO-GMP.<\/p>\n \u03a4\u03bf Ezedoc \u03c0\u03b1\u03c1\u03ad\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae WHO-GMP \u03bc\u03b5 \u03c0\u03bb\u03ae\u03c1\u03b7 \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03af\u03c9\u03c3\u03b7 COA. \u03a0\u03c1\u03b1\u03b3\u03bc\u03b1\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bc\u03b5 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ad\u03c2 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03ae, \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03ba\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>. Your statement descriptor when paying by card shows the regulated payment processor (a regulated card-payment processor), never \u201cMedsBase\u201d or any medication name.<\/p>\n <\/p>\n \u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 \u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n \u2705 \u039c\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b1 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u03c7\u03bf\u03bb\u03b7\u03c3\u03c4\u03b5\u03c1\u03cc\u03bb\u03b7\u03c2 Ezedoc<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 Ezetimibe<\/strong>.<\/p>","protected":false},"featured_media":56973,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3953],"product_tag":[4210,4211],"class_list":{"0":"post-56972","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-high-cholesterol-treatments","9":"product_tag-ezedoc","10":"product_tag-ezetimibe","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/56972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=56972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/56973"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=56972"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=56972"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=56972"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=56972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
\u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf Ezedoc;<\/h2>\n
\u0393\u03b9\u03b1 \u03c4\u03b9 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af\u03c4\u03b1\u03b9 \u03c4\u03bf Ezedoc;<\/h2>\n
\n
\u03a0\u03ce\u03c2 \u039b\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03b5\u03af \u03c4\u03bf Ezedoc;<\/h2>\n
\n
\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7<\/h2>\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n
\n
\u03a0\u03bf\u03b9\u03bf\u03c2 \u03b4\u03b5\u03bd \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03c0\u03b1\u03af\u03c1\u03bd\u03b5\u03b9 \u03c4\u03bf Ezedoc;<\/h2>\n
\n
\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n
\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\u039c\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03c0\u03ac\u03c1\u03c9 Ezedoc \u03b1\u03bd\u03c4\u03af \u03b3\u03b9\u03b1 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b7;<\/h3>\n
\u03a0\u03ce\u03c2 \u03c3\u03c5\u03b3\u03ba\u03c1\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03c4\u03bf Ezedoc \u03bc\u03b5 \u03c4\u03b7 \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03cc \u03c4\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c4\u03bf\u03c5 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03bf\u03c5 \u03bc\u03bf\u03c5;<\/h3>\n
\u039c\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03bf Ezedoc \u03c4\u03b1 \u03ad\u03bc\u03c6\u03c1\u03b1\u03b3\u03bc\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03b1 \u03b5\u03b3\u03ba\u03b5\u03c6\u03b1\u03bb\u03b9\u03ba\u03ac \u03b5\u03c0\u03b5\u03b9\u03c3\u03cc\u03b4\u03b9\u03b1;<\/h3>\n
\u03a0\u03cc\u03c4\u03b5 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03c0\u03b1\u03af\u03c1\u03bd\u03c9 \u03c4\u03bf Ezedoc;<\/h3>\n
\u03a0\u03c1\u03bf\u03ba\u03b1\u03bb\u03b5\u03af \u03c4\u03bf Ezedoc \u03bc\u03c5\u03ca\u03ba\u03cc \u03c0\u03cc\u03bd\u03bf \u03cc\u03c0\u03c9\u03c2 \u03c4\u03b1 \u03c3\u03c4\u03b1\u03c4\u03af\u03bd\u03b9\u03b1;<\/h3>\n
\u03a0\u03bf\u03cd \u03bc\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03b1\u03b3\u03bf\u03c1\u03ac\u03c3\u03c9 Ezedoc online;<\/h3>\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03a7\u03bf\u03bb\u03b7\u03c3\u03c4\u03b5\u03c1\u03af\u03bd\u03b7<\/h2>\n
\n
\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n
\n
\n\u2705 \u039c\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03bf\u03bd \u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ce\u03bd \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03c9\u03bd
\n\u2705 \u0391\u03c0\u03bf\u03c4\u03c1\u03ad\u03c0\u03b5\u03b9 \u03c4\u03b7\u03bd \u03b1\u03b8\u03b7\u03c1\u03bf\u03c3\u03ba\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7
\n\u2705 \u03a3\u03c5\u03bd\u03c4\u03b1\u03b3\u03bf\u03b3\u03c1\u03b1\u03c6\u03b5\u03af\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u0393\u03b9\u03b1\u03c4\u03c1\u03bf\u03cd\u03c2
\n\u2705 \u0395\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5<\/p>\n